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Mutated JAK activates a number of downstream pathways implicated in the proliferation and survival of malignant cells, including the signal transducers and activators of transcription (STATs).
The pervasive activation of the JAK-STAT pathway in myelofibrosis (MF) lent credence to the development JAK inhibitors. Two multicenter phase III clinical trials led to the approval of ruxolitinib, a first-in-class JAK1/JAK2 inhibitor, initially in MF, 2,3 and more recently as second-line therapy in hydroxyurea (HU)-resistant/intolerant polycythemia vera (PV). 4 In MF, ruxolitinib has been shown to reduce spleen size, constitutional symptoms burden, induce hematologic (especially anemia) improvements, reduce bone marrow fibrosis and JAK2 allele burden in a subset of patients, and significantly improve five-year survival.
Janus kinase inhibitors
A number of novel JAK-inhibitors have entered clinical trials for patients with MF. 5 Pacritinib, an oral dual JAK2 and FMS like tyrosine kinase 3 (FLT3) inhibitor has shown efficacy in reducing the spleen size and symptom burden in patients with intermediate-and high-risk MF 6-8 with only marginal worsening of anemia and thrombocytopenia, indicating that this agent could be administered in patients with MF with low platelets at baseline, which is an area of unmet need. Unfortunately, the pacritinib phase III study in MF was placed on hold by the US Food and Drug Administration (FDA) effective February 2016, after an interim analysis showed increased mortality secondary to cardiac events and intracranial bleeding.
Besides pacritinib, the clinical development of a number of other JAK2 inhibitors has been prematurely halted due to drug-emergent toxicities. These included peripheral neuropathy (seen with XL019), 9 Wernicke's encephalopathy (with fedratinib), 10 and various toxicities recorded with lestaurtinib.
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Momelotinib remains the only other JAK inhibitor undergoing evaluation in a phase III trial for patients with MF in the United States. In early phase trials, momelotinib showed significant clinical improvements in anemia, splenomegaly, and constitutional symptoms. 12 The primary toxicity associated with this agent was peripheral neuropathy. Momelotinib is currently being compared to ruxolitinib in a phase III trial evaluating frontline therapy in patients with International Prognostic Scoring System (IPSS) scores of intermediate-1 (Int-1) or -2 or high-risk MF who require therapy (NCT01969838). Other selective JAK2 inhibitors currently under evaluation in phase I/II trials in MF include NS018 and LY27A45445 (see Table 1 ). 
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Beyond Janus kinaseinhibition-combination treatments and various pathways
MPNs involve the constitutive activation of JAK-STAT signaling axis and its downstream effectors, including other JAK members, STAT3/5, mitogenactivated protein kinases (MAPK), and phosphoinositide 3-kinase (PI3K) (see Figure 1 ) that promote cellular proliferation, apoptosis, and drug resistance in patients with MF. [13] [14] [15] Independent parallel signaling pathways, including hedgehog 16 and histone deacetylase (HDAC) 17 interfere with cellular differentiation, hematopoiesis, and cell cycle regulation in MF. 20 (improved cytopenias), PI3K inhibitors 15 (reversal of marrow fibrosis), hedgehog inhibitors 21 (marked reduction in marrow fibrosis), and pegylated interferon (IFN) alfa-2a 22 (overcoming acquired resistance to IFN monotherapy).
Immunomodulatory drugs (IMiDs) lenalidomide and pomalidomide 23, 24 improve anemia and thrombocytopenia in patients with MF. In phase I/II trials, the combination of ruxolitinib and pomalidomide 25 showed a response rate of 12% with anemia and neuropathy being the major toxicities. Similarly, ruxolitinib in combination with lenalidomide 26 was associated with a slightly higher CI spleen response but prohibitive myelosuppression lead to early termination in a majority of patients.
We believe that to improve the tolerability a sequential rather than concomitant approach should be considered when contemplating combinations with ruxolitinib. We are currently exploring such a sequential Phase III study of pacritinib (PAC) versus best available therapy approach in ongoing ruxolitinib combination strategies (NCT01787487, NCT02267278) (see Table 1 ). 
Reversal or control of marrow fibrosis is
